ForPatients
by Roche

Bacterial Infection

A Study to Investigate the Intrapulmonary Lung Penetration of Nacubactam in Healthy Participants

Trial Status	Trial Runs In	Trial Identifier
Completed	1 Countries	NCT03182504 2016-004478-16 NP39750

The source of the below information is the publicly available website ClinicalTrials.gov. It has been summarised and edited into simpler language.

Trial Summary:

The purpose of this study is to characterize the intrapulmonary penetration of nacubactam in healthy volunteers. Nacubactam is a novel non-beta-lactam beta-lactamase inhibitor being developed as a combination therapy with the beta-lactam meropenem for the treatment of serious gram-negative bacterial infections. Adult male and female healthy participants will receive a single intravenous infusion of nacubactam co-administered with meropenem and then undergo a bronchoalveolar lavage (BAL) procedure to collect lung epithelial lining fluid (ELF) for measurement of intrapulmonary concentrations of nacubactam and meropenem.

Hoffmann-La Roche	Phase 1
Sponsor	Phase

NCT03182504 2016-004478-16 NP39750
Trial Identifiers

Eligibility Criteria:

Gender	Age	Healthy Volunteers
All	>= 18 Years & <= 60 Years	Accepts Healthy Volunteers